As part of collaborative research between The Netherlands Cancer Institute, Leiden University Medical Centre, UbiQ and the University of Amsterdam, van Kruijsbergen et al. report in Frontiers in Chemistry detailed protocols for the development of antibodies recognizing site-specific ubiquitin modifications.

The report describes considerations for antigen design (see also our UbiQ Block technology), screening and quality control experiments.

Strategy for Development of Site-Specific Ubiquitin Antibodies
Ila van Kruijsbergen1†, Monique P. C. Mulder2†, Michael Uckelmann3, Tibor van Welsem1, John de Widt3, Aldo Spanjaard4, Heinz Jacobs4, Farid El Oualid5, Huib Ovaa2* and Fred van Leeuwen1,6*
1Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, Netherlands
2Leiden Institute for Chemical Immunology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands
3Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands
4Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands
5UbiQ Bio BV, Amsterdam, Netherlands
6Department of Medical Biology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Front. Chem., 21 February 2020 | https://doi.org/10.3389/fchem.2020.00111